Collectively, whether number of metastatic lesions and ECOG performance status might be used as prognostic biomarkers for elderly patients with advanced NSCLC who received the treatment of PD-1 blockade monotherapy should be validated in prospective clinical trials subsequently. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.